agilon health, inc.

source: coverage-next-full ticker: AGL company: agilon health, inc. step: 01 title: Business Model & Overview created: 2026-06-04

Step 01 — Business Model & Overview: agilon health, inc. (AGL)

1. Company Summary

agilon health, inc. (NYSE: AGL) is a value-based care (VBC) enablement company that partners with independent primary care physician (PCP) groups to manage Medicare Advantage (MA) beneficiaries under a full-risk, global capitation model. Rather than owning clinics or employing physicians, agilon provides a platform — including payer contracting infrastructure, technology analytics, care management programs, and operational support — that allows existing community physicians to bear and benefit from full MA risk. [S1][S2]

Elevator pitch: agilon transforms fee-for-service community primary care physicians into capitated Medicare Advantage partners, keeping patients healthy and capturing the gap between capitation premiums and actual medical costs as "medical margin."

2. Value Chain Layer Map

Medicare Advantage Plans (Humana, UHC, BCBS, Aetna, etc.)
    │
    │  Per-member-per-month (PMPM) capitation payments
    ▼
agilon health Platform
    │  • Global capitation contracts with MA plans
    │  • Technology platform (analytics, risk-adjustment coding support)
    │  • Care management programs (high-risk patient identification)
    │  • Operational support (billing, quality, payer relations)
    │  • Shared financial risk structure with physician groups
    ▼
Physician Partner Groups (~30 independent groups, 12 states)
    │  • Primary care physician panels take on full financial risk
    │  • Revenue = capitation PMPM × covered members
    │  • Medical margin = capitation revenue − total medical costs
    ▼
Patients (Medicare Advantage beneficiaries, ~511K covered lives, FY2025)

Revenue flow: MA plans pay agilon's physician partner entities a fixed PMPM capitation for each enrolled member. agilon recognizes this full capitation as its revenue. Medical costs (hospitalizations, specialist care, pharmacy, etc.) are subtracted to calculate Medical Margin — the economic "gross profit" of the business. agilon receives a platform fee from the physician group's net economics; the physician group retains operating income after agilon's fee. [S2]

3. Business Model Components

3a. Risk-Based Enablement (RBE) Structure

The RBE structure allows agilon to consolidate full capitation revenue while keeping physicians autonomous — a critical differentiator vs. employed-physician models (Oak Street Health, ChenMed) and fee-for-service enablement models (Privia Health). [S8]

3b. Revenue Mechanics

• Revenue = Capitation PMPM × Total MA Members × 12 months
• PMPM rates are set annually by CMS through the MA bidding process, then negotiated between the MA plan and agilon's RBE
• Revenue risk-adjustment: capitation is adjusted for member acuity (HCC risk scores); risk-adjustment true-ups have been a material negative item in FY2024 and FY2025
• Part D (prescription drug) is included in capitation — a new and material cost driver following the Inflation Reduction Act changes effective 2024

3c. Medical Margin (Economic Gross Profit)

Capitation Revenue
  − Total Medical Costs (hospitalizations, specialists, pharmacy, Part D)
= Medical Margin

Medical Margin %  =  Medical Margin / Revenue

[S1][S2]

4. Geographic & Partnership Footprint

Strategy: agilon exited underperforming markets (notably Hawaii and California in FY2023) and continues rationalizing partnerships. FY2026 guidance assumes members shrink to ~430K as additional underperforming markets/contracts exit. [S2][S6]

5. Revenue Concentration

agilon's top MA plan partners are not individually disclosed, but Humana, UnitedHealth Group, Aetna (CVS), and BCBS affiliates collectively represent the majority of capitation revenue. Single-plan concentration risk is moderated by multi-payer contracting in most markets, but MA plan consolidation is a monitoring item. [S2]

6. Competitive Positioning

Key moat claim: Physician stickiness — once a physician group takes capitation risk via agilon's platform, switching costs are high (rebuilt payer relationships, analytics dependencies, working capital support). [S8]

7. Source Index

source: coverage-next-full ticker: AGL company: agilon health, inc. step: 12 title: Bull vs. Bear Analyst Debate created: 2026-06-04

Step 12 — Bull vs. Bear: agilon health, inc. (AGL)

Note: Transcripts not loaded. Bull/bear debate constructed from analyst consensus notes, broker research summaries, press release commentary, and news sources (coverage-next-full path).

1. Current Market Context

As of research date (2026-06-04):

• Stock price: ~$82.70 (post 1:25 reverse split; pre-split equivalent ~$3.31)
• Market cap: ~$1.38B
• Enterprise value: ~$1.30B
• Analyst mean price target: ~$58–60 (well below current price)
• Consensus: ~"Hold"
• Street distribution: roughly 3–5 Buy, 8–10 Hold, 2–3 Sell

The setup is unusual: AGL stock has rallied >2.5× from its post-guidance-suspension lows on Q1 2026 beat, and the stock now trades ABOVE the analyst mean target. This creates a bifurcated debate between momentum bulls (the turnaround is proving out) and fundamental skeptics (the ROIC story is still unproven; membership is shrinking; litigation overhang). [S5]

2. Bull Case Thesis

Argument B1: Q1 2026 MCR Proves the Turnaround is Real

Claim: Q1 2026 MCR of ~88% is not a seasonal artifact — it reflects AGL's portfolio rationalization working. The company exited ~85K members (net) in Q1 2026; those were the highest-MCR, most problematic markets. The remaining 426K members represent a quality book that sustainably generates $25–30/member/month medical margin.

Evidence: $149M medical margin in Q1 2026 on 426K members; EPS $1.80 vs. $0.93 consensus; FY2026 guidance raised post-Q1.

Bull price target: $90–95 (Benchmark target cited). Basis: 0.3× EV/Revenue (FY2026E $5.7B revenue) = $1.7B EV → ~$100/share. Or: 10× FY2027E Adj. EBITDA of ~$175M = ~$1.75B EV.

Argument B2: FY2026 Is the First Year of a Multi-Year Earnings Recovery

Claim: Adj. EBITDA is going from -$230M (FY2025) to +$20M (FY2026E) to potentially +$150–200M (FY2027E). This is a meaningful earnings trajectory that will attract multiple expansion as the company moves from "distressed turnaround" to "recovering growth" framing.

Evidence: Q1 2026 adj. EBITDA ~$55M annualizes to $220M — well above FY2026 guidance of $15–25M. Management explicitly guided to positive FY2026 adj. EBITDA for the first time in company history.

Argument B3: FY2026 MA Rate Increase (+7.2%) Is the Most Favorable in Years

Claim: The combination of AGL's contract resets (which include explicit Part D repricing) and the largest CMS base rate increase in years creates a macro tailwind that the FY2024–2025 cohort did not enjoy.

Evidence: CMS finalized FY2026 rate announcement at +7.2% effective base rate change; combined with contract resets, PMPM rates for remaining AGL markets should be materially higher in 2026 than 2025.

3. Bear Case Thesis

Argument B1: Q1 Is the Seasonally Best Quarter — Q2–Q4 Will Reveal the True Run-Rate

Claim: Q1 is always the best MCR quarter in Medicare Advantage because utilization (hospitalizations, procedures) is seasonally lowest in January–March. The Q1 2026 MCR of ~88% cannot be annualized; Q2–Q4 historically run 3–5 percentage points higher. FY2026 guidance of $15–25M adj. EBITDA (implying full-year medical margin ~$375M) requires Q2–Q4 to hold at MCR ~93–94%. That's far from guaranteed given recent medical cost trend experience.

Evidence: AGL's own recent history: Q1 2024 MCR 93.9% vs. full-year FY2024 MCR 96.6%; Q1 2023 MCR ~91% vs. full-year 93.8%. The seasonal pattern is real and meaningful.

Bear price target: $21 (JPMorgan cited). Basis: Discounted to ~0.3× book value + option value on turnaround.

Argument B2: Membership Contraction Limits Revenue Recovery Even If MCR Normalizes

Claim: AGL is guiding to ~430K members at FY2026 year-end — 18% below the FY2025 peak. Revenue will be ~$5.7B in FY2026 and $5.5–5.8B in FY2027 even in a recovery scenario. This is a business whose top line is shrinking, not growing. At the current stock price ($82 post-split), the market is pricing in a revenue recovery that requires new partnership additions the company has not yet committed to.

Evidence: FY2026 guidance implies flat-to-declining members; FY2027 new partner additions would require 2–3 year ramp periods to add meaningful revenue; revenue decline from peak unlikely to reverse until FY2028+.

Argument B3: Securities Litigation + Balance Sheet Fragility Create Asymmetric Downside Risk

Claim: The securities class action (class period Feb 2024–Aug 2025; filed Dec 2025) could result in a $50–200M settlement that materially impacts the cash balance ($182M FY2025). At the guided ~$125M FY2026 year-end cash, a $100M settlement payment would leave AGL below minimum operating liquidity, potentially requiring a dilutive equity raise at an inopportune time.

Evidence: AGL acknowledged the lawsuit in its FY2025 10-K. Class period aligns with a $250M+ guidance miss. Similarly-sized MA misstatement cases have settled at $40–150M range.

4. Analyst Debate Summary

5. Bull Case — 3 Bullets

• Q1 2026 MCR of ~88% demonstrates portfolio rationalization is working: Exiting ~85K underperforming members dramatically improved the remaining book's economics, and FY2026 contract resets explicitly price in Part D and risk-adjustment realities for the first time — creating a structurally cleaner earnings base.
• First guided positive EBITDA year (FY2026 $15–25M) marks an inflection that should command multiple expansion: As AGL transitions from "cash-burning turnaround" to "EBITDA-positive platform company," it should re-rate from deep distress multiples toward healthcare services comps (5–10× EBITDA), which implies meaningful upside from current levels if guidance holds.
• +7.2% CMS MA base rate in FY2026 provides the largest external PMPM tailwind in company history: Combined with AGL's contract resets, this creates an asymmetric setup where even modest MCR normalization produces outsized medical margin — the bull case is that Q2–Q4 2026 remain more favorable than historical seasonality suggests, driven by the MA rate increase absorbing the residual V28 headwind.

6. Bear Case — 3 Bullets

• Q1 is the seasonally best Medicare Advantage quarter; the ~88% MCR is not the sustainable run-rate: Q2–Q4 historically run 3–5 percentage points above Q1 on MCR; if FY2026 full-year MCR averages 95%+ (as in FY2024), the $375M guided medical margin collapses to near-zero, and the securities class action + balance sheet fragility could force a dilutive equity raise.
• Membership is planned to shrink to 430K in FY2026 (vs. 526K peak) and recovery requires 2–3 year physician group ramp: Revenue will be structurally below $6B through at least FY2028, and the current ~$1.38B market cap implies >15× EV/FY2026 EBITDA — a premium multiple for a still-recovering, litigation-laden company with a largely unproven new CEO.
• Securities class action creates $50–200M tail liability at precisely the moment when cash is thin (~$125M guided FY2026 year-end): Any settlement or adverse legal development in FY2026–2027 could exhaust liquidity and trigger a dilutive capital raise, re-testing the stock near its prior crisis lows.

7. Source Index